Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report ; volume:14 ; number:1 ; day:4 ; month:2 ; year:2014 ; pages:9-11 ; date:3.2014
Drugs in R & D ; 14, Heft 1 (4.2.2014), 9-11, 3.2014
- Creator
-
Urru, S. A. M.
Mariotti, E.
Carta, P.
Massidda, S.
Marcias, M.
Murru, R.
Sanna, P.
Angelucci, E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-014-0036-x
- URN
-
urn:nbn:de:101:1-2019063008564537035090
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Urru, S. A. M.
- Mariotti, E.
- Carta, P.
- Massidda, S.
- Marcias, M.
- Murru, R.
- Sanna, P.
- Angelucci, E.
- SpringerLink (Online service)
Other Objects (12)
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma